



OPEN ACCESS

Short report

Likely pathogenic structural variants in genetically unsolved patients with retinitis pigmentosa revealed by long-read sequencing

Yusuke Sano ,^{1,2} Yoshito Koyanagi ,^{1,3} Jing Hao Wong,² Yusuke Murakami,¹ Kohta Fujiwara,¹ Mikiko Endo,⁴ Tomomi Aoi,⁴ Kazuki Hashimoto,⁵ Toru Nakazawa,^{5,6} Yuko Wada,⁷ Shinji Ueno,⁸ Dan Gao,⁹ Akira Murakami,⁹ Yoshihiro Hotta,¹⁰ Yasuhiro Ikeda,¹¹ Koji M Nishiguchi,⁸ Yukihide Momozawa,⁴ Koh-Hei Sonoda,¹ Masato Akiyama,^{3,12} Akihiro Fujimoto 

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jmedgenet-2022-108428>).

For numbered affiliations see end of article.

Correspondence to

Dr Akihiro Fujimoto, Department of Human Genetics, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; afujimoto@m.u-tokyo.ac.jp
Dr Masato Akiyama; akiyama.masato.588@m.kyushu-u.ac.jp

Received 5 January 2022
Accepted 14 May 2022
Published Online First 15 June 2022

SUMMARY

Despite the successful identification of causative genes and genetic variants of retinitis pigmentosa (RP), many patients have not been molecularly diagnosed. Our recent study using targeted short-read sequencing showed that the proportion of carriers of pathogenic variants in *EYS*, the cause of autosomal recessive RP, was unexpectedly high in Japanese patients with unsolved RP. This result suggested that causative genetic variants, which are difficult to detect by short-read sequencing, exist in such patients. Using long-read sequencing technology (Oxford Nanopore), we analysed the whole genomes of 15 patients with RP with one heterozygous pathogenic variant in *EYS* detected in our previous study along with structural variants (SVs) in *EYS* and another 88 RP-associated genes. Two large exon-overlapping deletions involving six exons were identified in *EYS* in two patients with unsolved RP. An analysis of an independent patient set (n=1189) suggested that these two deletions are not founder mutations. Our results suggest that searching for SVs by long-read sequencing in genetically unsolved cases benefits the molecular diagnosis of RP.

INTRODUCTION

Retinitis pigmentosa (RP; OMIM:268000) is a prevailing form of inherited retinal dystrophy (IRD) and a major cause of blindness worldwide. RP is inherited in autosomal dominant, autosomal recessive or X-linked inheritance patterns following Mendel's law of inheritance, with very few exceptions.¹ So far, more than 80 genes have been reported as genetic causes of RP. As with other Mendelian disorders,^{2,3} 40%~70% of patients with RP do not have a molecular diagnosis.^{1,4-6} Nevertheless, advances in sequencing technology have enabled scientists to reveal the genetic causes of RP.^{1,6-9} Previous studies have demonstrated that *EYS*, *USH2A*, *RPGR* and *RHO* are the frequent causative genes of RP across ethnicities.^{1,6,7} For Japanese patients with RP, *EYS*, which is the cause of autosomal recessive RP (ARRP), has been reported as the most frequent causative gene.^{6,10}

We previously reported the targeted short-read sequencing of 83 RP-associated genes in 1204

Japanese patients with RP.¹¹ In that study, custom-made multiplex PCR-based targeted resequencing was performed using a next-generation sequencer. As a result, causative genes were determined in 29.6% of patients; however, the remaining cases remained unsolved. Importantly, the study indicated that more than a quarter of unsolved patients had one pathogenic variant in *EYS*,¹¹ suggesting that *EYS* is a promising candidate as the causative gene.¹¹ Although the exact reason for this observation has not been clarified, it is possible that variants that are difficult to identify by short-read targeted resequencing, such as structural variants (SVs) and intronic variants, are another causative variant. Indeed, SVs, intronic variants and hypomorphic variants have been uncovered as a second pathogenic variant in patients with IRD.^{9,12-15} Therefore, we considered whether carriers of pathogenic variants in *EYS* have second causative variants that are not detectable by short-read target sequencing.¹¹

Long-read sequencing technology has several advantages compared with short-read sequencing, such as accurate SV detection.^{16,17} In order to increase the number of solved patients with RP and to deepen our knowledge about the genetic basis of RP, here we conducted a sequencing study of 15 patients with RP who are carriers of one pathogenic variant in *EYS* using long-read sequencing and examined the frequencies of the identified SVs from an independent patient group in our previous study (n=1189).¹¹

MATERIALS AND METHODS

Study patients

The clinical diagnosis of RP was based on the patient's history, visual field and electroretinography outcomes, as well as ophthalmological findings by trained ophthalmologists. We selected 15 cases (figure 1) with heterozygous pathogenic variants in *EYS* from our previous study¹¹ for whole-genome long-read sequencing. To assess founder effects of the identified variants in the Japanese population, we examined the frequencies of the SVs in the independent patient group from our previous study (n=1189).¹¹ For validation purposes, we



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Sano Y, Koyanagi Y, Wong JH, et al. *J Med Genet* 2022;**59**:1133-1138.




Figure 1 Details of the sample selection. Of the 1204 cases included in the previous study, 508 were patients with retinitis pigmentosa (RP) at Kyushu University Hospital. Among them, we selected 101 genetically unresolved cases with heterozygous pathogenic variants (known pathogenic or loss of function variants) in the *EYS* gene. Among these cases, 80 cases had missense variants of unknown pathogenic significance in addition to the above-mentioned pathogenic variants. Considering the possible pathogenesis of missense variants not considered pathogenic in our previous study, patients with such variants were excluded. Of the remaining 21 cases, 15 cases with a sufficient amount of DNA were selected for long-read sequencing using the Oxford Nanopore sequencer.

performed multiplex PCR-based targeted sequencing¹⁸ using the independent RP patient set.

Library preparation and sequencing for whole-genome long-read sequencing

Libraries for long-read sequencing were prepared using the SQK-LSK109 Ligation Sequencing Kit (Oxford Nanopore Technologies) following the manufacturer's protocol, and the sequencing itself was performed according to the manufacturer's protocol using FLO-MIN106 R9.4.1 flow cells (Oxford Nanopore Technologies) for 96 hours. The number of sequencing runs was adjusted to obtain at least 45 Gb of data for each sample (online supplemental table S1).

Identification and validation of SVs in RP-associated genes

Base-calling was performed using Guppy V4.4.1 (Oxford Nanopore Technologies). We mapped reads to the reference sequence (GRCh38) and focused on SVs, because long-read sequencing does not have high detection accuracy for single-nucleotide variants (SNVs) or short indels.^{17–19} We used the CAMPHOR¹⁷ pipeline to detect indels (≥ 50 bp), inversions, duplications and translocations. After the variant-calling, SVs longer than 1 Mb were excluded due to the possibility of variant-calling errors.

To select candidate pathogenic SVs for RP, we analysed *EYS* and another 88 RP-associated genes listed in the Retinal Information Network (RetNet) (<https://sph.uth.edu/retnet/>) as of 14 April 2021 (online supplemental table S2). We proceeded to search for the following types of SVs: (1) SVs in the coding region of *EYS*, which is one of the most promising candidate causative

genes, (2) SVs which overlap human retina-specific exons of *EYS* that may play important roles in retinal diseases,²⁰ (3) SVs within 500 bp of the exon boundaries of *EYS* that could affect splicing or promoter functions and (4) SVs in the RefSeq coding regions of other RP genes that could be causative variants. Variant classification was performed for the detected variants according to the guidelines of the American College of Medical Genetics and Genomics (ACMG).²¹

To prioritise pathogenic SVs, the allele frequencies (AFs) of the SVs were compared with those in our in-house long-read whole-genome sequencing data (53 Japanese healthy control samples), Genome Aggregation Database (gnomAD SVs v2.1) and dbVar database.²² We removed variants using the following criteria: (1) variants found in the 53 Japanese control samples, and (2) variants with an AF $> 0.5\%$ for recessive genes and $> 0.01\%$ for dominant genes in gnomAD SVs or dbVar.

Among the SVs overlapping the *EYS* region, we excluded three large SVs (110 Mb inversion, 82 Mb inversion and 97 Mb translocation) to avoid variant-calling errors using the following criteria: (1) the size of the SVs was too large, (2) there were only two reads supporting the breakpoints of the SVs and (3) the 1 kb sequence around the breakpoint was aligned with multiple regions of the human genome and likely to be a repeat region. We noted that the excluded SVs were less likely to be pathogenic, since their breakpoints did not overlap with the regions of RP-associated genes.

We tried to identify SNVs from long-read data and compared the results with our previous study¹¹ (online supplemental table S3). Long-read sequencing identified a much larger number of SNVs than short-read sequencing, suggesting a higher error rate in the former. Therefore, we did not take SNVs into consideration in the current study.

To validate the identified SVs, we amplified the SV junction regions by PCR using KOD Multi&Epi enzyme (TOYOBO), and amplicons were subjected to Sanger sequencing.

To examine the frequencies of the SVs in the independent patient group ($n=1189$),¹¹ we performed multiplex PCR-based targeted sequencing. Three types of PCR primer sets were designed for each of the identified SVs to amplify the upstream breakpoint regions, downstream breakpoint regions and deleted regions of the large deletions (online supplemental figure 1 and table S4). The details of the sequencing method have been described previously.¹⁸

RESULTS

We selected 15 patients with RP with one pathogenic variant in *EYS* from our previous study¹¹ and confirmed that all of them had typical RP. We performed whole-genome sequencing with the Oxford Nanopore long-read sequencer. The average number of reads and their lengths were 6 623 354.7 and 8136.7 bp, respectively (online supplemental figure 2, table S1), and 93.7% of the reads were aligned to the human reference genome (GRCh38) (online supplemental table S5). The mean depth of the *EYS* region was 16.5. The most the *EYS* region (94.1%) was covered by ≥ 10 reads (online supplemental figure 3, table S6).

We confirmed that the pathogenic variants of *EYS* detected in our previous targeted resequencing study¹¹ could be found by long-read sequencing all patients (online supplemental figure 4, table S7). We then focused on identified SVs. In the 15 patients with RP sequenced, 46 899 SVs consisting of 22 786 deletions, 22 790 insertions, 89 inversions, 765 duplications and 469 translocations were identified across the genome. We observed 176 exon-overlapping SVs per patient on average, which included

Table 1 Summary of SVs identified in RP-associated genes

Chr	Start	End	Length (bp)	Type of SV	Gene	Overlap with coding regions of RP-associated genes	Distance (bp)*	Frequency in in-house data	Frequency in gnomAD	Frequency in dbVar	Sample
chr6	63 957 115	63 958 454	1340	Deletion	EYS	+	-	14%	-	-	OPH217, OPH517, OPH641, OPH690, OPH861, OPH125, OPH556, OPH595, OPH693
chr6	65 001 113	65 005 820	4708	Deletion	EYS	+	-	21%	-	-	OPH125, OPH217, OPH693, OPH556
chr6	65 550 144	65 552 138	1995	Deletion	EYS	+	-	81%	-	-	All samples
chr6	65 689 153	65 694 794	5642	Deletion	EYS	+	-	31%	-	-	OPH125, OPH176, OPH531, OPH556, OPH566, OPH641, OPH693, OPH831, OPH861, OPH332
chr6	63 942 754	64 337 844	395 091	Deletion	EYS	+	-	-	-	-	OPH861
chr6	64 423 168	64 798 962	375 795	Deletion	EYS	+	-	-	-	-	OPH641
chr6	65 454 074	65 454 074	305	Insertion	EYS	+	-	17%	-	-	OPH217, OPH125, OPH447, OPH517, OPH556, OPH566, OPH690, OPH831, OPH861, OPH693
chr6	64 296 539	64 296 632	94	Deletion	EYS	-	66	-	-	56%	OPH556, OPH531, OPH517, OPH595, OPH176, OPH641, OPH566, OPH693
chr6	65 204 982	65 205 044	63	Deletion	EYS	-	157	-	2.4%	-	OPH566, OPH176, OPH690, OPH125
chr6	65 564 961	65 565 284	324	Deletion	EYS	-	154	80%	-	-	All samples
chr6	64 295 413	64 295 413	118	Insertion	EYS	-	148	27%	-	-	All samples
chr6	65 278 329	65 278 329	59	Insertion	EYS	-	59	-	2.7%	-	All samples
chr8	10 607 821	10 608 503	683	Deletion	RPL11	+	-	-	-	-	OPH690
chr8	10 610 105	10 610 105	94	Insertion	RPL11	+	-	15%	-	-	All samples
chr19	7 450 130	7 451 150	1021	Duplication	ARHGGEF18	+	-	-	-	7.2%	OPH861, OPH831, OPH693, OPH690, OPH566, OPH556, OPH531, OPH517, OPH595

*The shortest distance between the exon boundary and SV breakpoint.
RP, retinitis pigmentosa; SV, structural variant.




Figure 2 The causative structural variants (SVs) in *EYS*. (A) A schematic diagram of heterozygous deletions (top), an integrative genomics viewer (IGV) visualisation of the breakpoints of deletions (middle), and the exact breakpoint sequences confirmed by Sanger sequencing (bottom) in OPH641/OPH861 are shown. In each patient, 4 bp (OPH641)/6 bp (OPH861) insertions were identified within the deletion breakpoints. For example, exon. (B) The genetic elements to which the breakpoints belong to are shown. The downstream breakpoint of the deletion in OPH861 belongs in a repetitive region, and others belong in Long Interspersed Elements (LINE). Red and blue bars display the downstream/upstream breakpoint junctions. The dashed rectangles indicate the genetic elements where the breakpoints are localised.

103 deletions, 44 insertions, 7 inversions, 10 duplications and 12 translocations (online supplemental table S8). Next, we focused on SVs overlapping 89 RP-associated genes and found 15 candidate SVs (table 1). In the *ARRP* genes, 12 candidate SVs in *EYS* (9 deletions, 3 insertions), 1 deletion and 1 insertion in *RPIL1*, and 1 duplication in *ARHGEF18* were identified. The three deletions and two insertions in *EYS* did not overlap with the coding region but were within 500 bp of an exon (table 1). However, no exon-overlapping SVs were detected in autosomal dominant and X-linked recessive RP genes.

Two large exon-overlapping deletions in *EYS* were found in OPH641 and OPH861 (figure 2A). The lengths of the identified deletions were approximately 376 kb and 395 kb in OPH641 and OPH861, respectively. We performed Sanger sequencing and detected the exact breakpoint sequences for each SV. One deletion which involved six exons (exon 23–28) was accompanied by a 4 bp insertion within the breakpoints (NM_001142800.1:c.3443+14_421_5927+13_006delinsTCAT; figure 2A). This deleted region fully encompasses and overlaps a region in which an inverted duplication was previously reported.²³ Similarly, a 6 bp insertion within the breakpoints was found in the other deletion that overlapped with six exons (exon 30–35) of *EYS* (NM_001142800.1:c.6079–30740_7055+41_631delinsCATAAT; figure 2A). The breakpoints of both SVs were located in repetitive sequences (figure 2B). Insertions of short fragments were detected at the breakpoints, which suggests that the insertions were caused by fork stalling and template switching (FoSTeS)/microhomology-mediated break-induced replication (MMBIR).²⁴ According to the ACMG guidelines,²¹ the PVS1 and PM2 criteria were applied to these SVs, and they were considered likely pathogenic. We also confirmed the pathogenicity of SNVs identified in our previous study (Supplementary Note). Considering that two causative variants were present in the *ARRP* causative gene, we regarded *EYS* as the causative gene

for both OPH641 and OPH861. Clinical information for these two patients is provided in the Supplemental material (online supplemental figure 5). Both probands were sporadic cases according to the medical interviews. Although we were unable to investigate the segregation of the SVs with phenotypes in the pedigrees, this family history is consistent with the *ARRP* gene (*EYS*) being the causative gene. For the other thirteen candidate SVs for the *ARRP* gene, three control data (in-house, gnomAD SVs, dbVar) were used to prioritise variants by AF. A 683 bp heterozygous deletion in *RPIL1* found in OPH690 remained, and the other 12 candidates were excluded. According to the ACMG guidelines,²¹ the PVS1 and PM2 criteria were applied to this SV, and it was considered likely pathogenic. However, the other pathogenic variants in *RPIL1* were not detected in OPH690 by our previous targeted resequencing (online supplemental table S9),¹¹ therefore, we did not consider *RPIL1* as the causative gene for this patient.

Finally, we examined the frequencies of the two large SVs in *EYS* in other patients with RP. We conducted multiplex PCR-based targeted sequencing¹⁸ to evaluate these SVs in 1189 independent Japanese patients with RP. However, the two SVs were not detected, suggesting that they are not founder mutations.

DISCUSSION

In this study, we identified likely pathogenic SVs in two previously unsolved RP cases by long-read sequencing. The proportion of patients with a new molecular diagnosis was 2 out of 15, which is consistent with previous reports using short-read whole-genome sequencing (4.8%–12.5%).^{23 25}

Short-read and long-read sequencing can be applied to whole-genome sequencing. Although the former has the advantage of detecting SNVs and short indels, functional experiments are generally required to assess the causality of intronic variants. On

the other hand, long-read sequencing may identify pathogenic SVs, such as exon-overlapping SVs. Indeed, our study identified two likely pathogenic SVs. Although the utility of long-read sequencing for Mendelian diseases is not well established, this study indicates that long-read sequencing contributes to the molecular diagnosis of Mendelian diseases. Our previous and current studies have comprehensively investigated SNVs and short indels in the coding regions and SVs in *EYS* for 15 cases.¹¹ However, 87% (13/15) of the cases still remain unsolved. Considering that variants in coding regions were well investigated with sufficient coverage (online supplemental table S6), variants in non-coding regions could be the cause for these patients.

This study did not analyse intronic SNVs for three reasons: (1) pathogenic deep intronic *EYS* variants have not been reported previously, (2) the pathogenicity of intronic variants requires functional validation and (3) long-reads sequencing does not have sufficient accuracy for SNV identification. While long-read sequencing has contributed to molecular diagnosis in some cases, an inadequate search for variants in deep introns may result in the low detection rate of pathogenic variants. Therefore, further evaluation of non-coding regions in patients with unresolved RP by short-read sequencing and functional validation should increase the number of genetically solved patients. Additionally, an analysis of other candidate genes is recommended.

Another limitation of this study is that the haplotypes of the pathogenic variants in the patients could not be examined. A segregation analysis of the patients observed in the present study will further clarify the impact of the identified SVs.

In conclusion, we identified likely pathogenic SVs in an *ARRP* gene by long-read sequencing. Our results imply that searching for SVs and the comprehensive evaluation of non-coding regions in genetically unsolved cases will contribute to the molecular diagnosis of RP.

Author affiliations

¹Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan

²Department of Human Genetics, The University of Tokyo, Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan

³Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan

⁴Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan

⁵Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan

⁶Department of Advanced Ophthalmic Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan

⁷Yuko WADA Eye Clinic, Sendai, Japan

⁸Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

⁹Department of Ophthalmology, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan

¹⁰Department of Ophthalmology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

¹¹Department of Ophthalmology, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki, Japan

¹²Department of Ocular Pathology and Imaging Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Acknowledgements The super-computing resource was provided by the Human Genome Centre, Institute of Medical Science, the University of Tokyo.

Contributors MA and AF designed the study. YS performed long-read sequencing. YS, YK and AF analysed the data. YS, MA and AF contributed to data interpretation. ME, TA and Y Momozawa performed Multiplex PCR-based target sequencing. YK, Y Murakami, KF, KH, TN, YW, SU, DG, AM, YH, YI, KMN and KHS collected the samples. YS, JHW, MA and AF contributed to the manuscript preparation and editing. All authors approved the final manuscript.

Funding This research was supported by AMED under Grant Number JP21km0908001 (A.F.) and by the Japanese Retinitis Pigmentosa Society (M.A.).

Competing interests None declared.

Patient consent for publication Obtained.

Ethics approval The ethics committees of Kyushu University Hospital, the University of Tokyo, and all collaborating hospitals have approved this study. All participants have provided written consent to participate in the study. This study was conducted following the principles of the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Yusuke Sano <http://orcid.org/0000-0003-2023-7630>

Yoshito Koyanagi <http://orcid.org/0000-0001-5559-6305>

Akihiro Fujimoto <http://orcid.org/0000-0002-0075-0800>

REFERENCES

- 1 Verbakel SK, van Huet RAC, Boon CJF, den Hollander AI, Collin RWJ, Klaver CCW, Hoyng CB, Roepman R, Klevering BJ. Non-Syndromic retinitis pigmentosa. *Prog Retin Eye Res* 2018;66:157–86.
- 2 Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, Braxton A, Beuten J, Xia F, Niu Z, Hardison M, Person R, Bekheirnia MR, Leduc MS, Kirby A, Pham P, Scull J, Wang M, Ding Y, Plon SE, Lupski JR, Beaudet AL, Gibbs RA, Eng CM. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. *N Engl J Med* 2013;369:1502–11.
- 3 Willig LK, Petrikov JE, Smith LD, Saunders CJ, Thiffault I, Miller NA, Soden SE, Cakici JA, Herd SM, Twist G, Noll A, Creed M, Alba PM, Carpenter SL, Clements MA, Fischer RT, Hays JA, Kilbride H, McDonough RJ, Rosterman JL, Tsai SL, Zellmer L, Farrow EG, Kingsmore SF. Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings. *Lancet Respir Med* 2015;3:377–87.
- 4 Ge Z, Bowles K, Goetz K, Scholl HPN, Wang F, Wang X, Xu S, Wang K, Wang H, Chen R. NGS-based molecular diagnosis of 105 eyeGENE® probands with retinitis pigmentosa. *Sci Rep* 2015;5:1–9.
- 5 Zhao L, Wang F, Wang H, Li Y, Alexander S, Wang K, Willoughby CE, Zaneveld JE, Jiang L, Soens ZT, Earle P, Simpson D, Silvestri G, Chen R. Next-Generation sequencing-based molecular diagnosis of 82 retinitis pigmentosa probands from Northern Ireland. *Hum Genet* 2015;134:217–30.
- 6 Oishi M, Oishi A, Gotoh N, Ogino K, Higasa K, Iida K, Makiyama Y, Morooka S, Matsuda F, Yoshimura N. Comprehensive molecular diagnosis of a large cohort of Japanese retinitis pigmentosa and Usher syndrome patients by next-generation sequencing. *Invest Ophthalmol Vis Sci* 2014;55:7369–75.
- 7 Martin-Merida I, Avila-Fernandez A, Del Pozo-Valero M, Blanco-Kelly F, Zurita O, Perez-Carro R, Aguilera-Garcia D, Riveiro-Alvarez R, Arteché A, Trujillo-Tiebas MJ, Tahsin-Swafiri S, Rodriguez-Pinilla E, Lorda-Sanchez I, Garcia-Sandoval B, Corton M, Ayuso C. Genomic landscape of sporadic retinitis pigmentosa: findings from 877 Spanish cases. *Ophthalmology* 2019;126:1181–8.
- 8 Pieras JJ, Barragán I, Borrego S, Audo I, González-Del Pozo M, Bernal S, Baiget M, Zeitz C, Bhattacharya SS, Antiñolo G. Copy-Number variations in *EYS*: a significant event in the appearance of arRP. *Invest Ophthalmol Vis Sci* 2011;52:5625–31.
- 9 Zampaglione E, Kinde B, Place EM, Navarro-Gomez D, Maher M, Jamshidi F, Nassiri S, Mazzone JA, Finn C, Schlegel D, Comander J, Pierce EA, Bujakowska KM. Copy-number variation contributes 9% of pathogenicity in the inherited retinal degenerations. *Genet Med* 2020;22:1079–87.
- 10 Hosono K, Ishigami C, Takahashi M, Park DH, Hirami Y, Nakanishi H, Ueno S, Yokoi T, Hikoya A, Fujita T, Zhao Y, Nishina S, Shin JP, Kim IT, Yamamoto S, Azuma N, Terasaki H, Sato M, Kondo M, Minooshima S, Hotta Y. Two novel mutations in the *EYS* gene are possible major causes of autosomal recessive retinitis pigmentosa in the Japanese population. *PLoS One* 2012;7:e31036.
- 11 Koyanagi Y, Akiyama M, Nishiguchi KM, Momozawa Y, Kamatani Y, Takata S, Inai C, Iwasaki Y, Kumano M, Murakami Y, Omodaka K, Abe T, Komori S, Gao D, Hirakata T, Kurata K, Hosono K, Ueno S, Hotta Y, Murakami A, Terasaki H, Wada Y, Nakazawa

- T, Ishibashi T, Ikeda Y, Kubo M, Sonoda K-H. Genetic characteristics of retinitis pigmentosa in 1204 Japanese patients. *J Med Genet* 2019;56:662–70.
- 12 Fadaie Z, Whelan L, Ben-Yosef T, Dockery A, Corradi Z, Gilissen C, Haer-Wigman L, Corominas J, Astuti GDN, de Rooij L, van den Born LI, Klaver CCW, Hoyng CB, Wynne N, Duignan ES, Kenna PF, Cremers FPM, Farrar GJ, Roosing S. Whole genome sequencing and in vitro splice assays reveal genetic causes for inherited retinal diseases. *NPJ Genom Med* 2021;6.
 - 13 Van Schil K, Naessens S, Van de Sompele S, Carron M, Aslanidis A, Van Cauwenbergh C, Kathrin Mayer A, Van Heetvelde M, Bauwens M, Verdin H, Coppieters F, Greenberg ME, Yang MG, Karlstetter M, Langmann T, De Preter K, Kohl S, Cherry TJ, Leroy BP, De Baere E, CNV Study Group. Mapping the genomic landscape of inherited retinal disease genes prioritizes genes prone to coding and noncoding copy-number variations. *Genet Med* 2018;20:202–13.
 - 14 Jespersgaard C, Fang M, Bertelsen M, Dang X, Jensen H, Chen Y, Bech N, Dai L, Rosenberg T, Zhang J, Møller LB, Tümer Z, Brøndum-Nielsen K, Grønskov K. Molecular genetic analysis using targeted NGS analysis of 677 individuals with retinal dystrophy. *Sci Rep* 2019;9:1–7.
 - 15 Ellingford JM, Horn B, Campbell C, Arno G, Barton S, Tate C, Bhaskar S, Sergouniotis PI, Taylor RL, Carss KJ, Raymond LFL, Michaelides M, Ramsden SC, Webster AR, Black GCM. Assessment of the incorporation of CNV surveillance into gene panel next-generation sequencing testing for inherited retinal diseases. *J Med Genet* 2018;55:114–21.
 - 16 Zhou A, Lin T, Xing J. Evaluating nanopore sequencing data processing pipelines for structural variation identification. *Genome Biol* 2019;20:1–13.
 - 17 Fujimoto A, Wong JH, Yoshii Y, Akiyama S, Tanaka A, Yagi H, Shigemizu D, Nakagawa H, Mizokami M, Shimada M. Whole-Genome sequencing with long reads reveals complex structure and origin of structural variation in human genetic variations and somatic mutations in cancer. *Genome Med* 2021;13:1–15.
 - 18 Momozawa Y, Akiyama M, Kamatani Y, Arakawa S, Yasuda M, Yoshida S, Oshima Y, Mori R, Tanaka K, Mori K, Inoue S, Terasaki H, Yasuma T, Honda S, Miki A, Inoue M, Fujisawa K, Takahashi K, Yasukawa T, Yanagi Y, Kadonosono K, Sonoda K-H, Ishibashi T, Takahashi A, Kubo M. Low-Frequency coding variants in CETP and CFB are associated with susceptibility of exudative age-related macular degeneration in the Japanese population. *Hum Mol Genet* 2016;25:5027–34.
 - 19 Sedlazeck FJ, Lee H, Darby CA, Schatz MC. Piercing the dark matter: bioinformatics of long-range sequencing and mapping. *Nat Rev Genet* 2018;19:329–46.
 - 20 Farkas MH, Grant GR, White JA, Sousa ME, Consugar MB, Pierce EA. Transcriptome analyses of the human retina identify unprecedented transcript diversity and 3.5 Mb of novel transcribed sequence via significant alternative splicing and novel genes. *BMC Genomics* 2013;14:486.
 - 21 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. *Genet Med* 2015;17:405–24.
 - 22 Lappalainen I, Lopez J, Skipper L, Hefferon T, Spalding JD, Garner J, Chen C, Maguire M, Corbett M, Zhou G, Paschall J, Ananiev V, Flicek P, Church DM, DbVar CDM. DbVar and DGVa: public Archives for genomic structural variation. *Nucleic Acids Res* 2013;41:D936–41.
 - 23 Nishiguchi KM, Tearle RG, Liu YP, Oh EC, Miyake N, Benaglio P, Harper S, Koskineemi-Kuendig H, Venturini G, Sharon D, Koenekoop RK, Nakamura M, Kondo M, Ueno S, Yasuma TR, Beckmann JS, Ikegawa S, Matsumoto N, Terasaki H, Berson EL, Katsanis N, Rivolta C. Whole genome sequencing in patients with retinitis pigmentosa reveals pathogenic DNA structural changes and NEK2 as a new disease gene. *Proc Natl Acad Sci U S A* 2013;110:16139–44.
 - 24 Zhang F, Khajavi M, Connolly AM, Towne CF, Batish SD, Lupski JR. The DNA replication FoSTeS/MMBIR mechanism can generate genomic, genic and exonic complex rearrangements in humans. *Nat Genet* 2009;41:849–53.
 - 25 Carss KJ, Arno G, Erwood M, Stephens J, Sanchis-Juan A, Hull S, Megy K, Grozeva D, Dewhurst E, Malka S, Plagnol V, Penkett C, Stirrups K, Rizzo R, Wright G, Josifova D, Bitner-Glindzicz M, Scott RH, Clement E, Allen L, Armstrong R, Brady AF, Carmichael J, Chitre M, Henderson RHH, Hurst J, MacLaren RE, Murphy E, Paterson J, Rosser E, Thompson DA, Wakeling E, Ouwehand WH, Michaelides M, Moore AT, Webster AR, Raymond FL, NIHR-BioResource Rare Diseases Consortium. Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease. *Am J Hum Genet* 2017;100:75–90.